Welcome to our dedicated page for Gritstone bio news (Ticker: $GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gritstone bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gritstone bio's position in the market.
Gritstone bio, Inc. (Nasdaq: GRTS) will report its first-quarter 2024 financial results and provide corporate updates on May 9, 2024. The company, a clinical-stage biotechnology firm focused on developing potent vaccines, will hold a conference call and webcast at 4:30 pm ET on the same day. Interested parties can access the event via phone or webcast.
Gritstone bio presented updated Phase 1 data at ESCMID Global 2024, showcasing the durability and broad utility of its self-amplifying mRNA COVID-19 vaccine. IgG levels, neutralizing antibodies, and T cell responses persisted for at least 12 months. The samRNA vaccine exhibited strong immunogenicity across different patient populations, including those living with HIV.
Gritstone bio, Inc. (Nasdaq: GRTS) appointed Stephen Webster, a finance executive with 30 years of experience, to its Board of Directors. Webster's expertise in raising capital and business development will be important as the company prepares for Phase 2 GRANITE data and potential growth. Steve Krognes will not stand for re-election at the 2024 Annual Meeting.
